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To treat or not to treat with antifungal agents?The paper of Tom Hillard et al. in this Journal reports
experiences with the new antifungal drug voriconazole in
patients with CF. In this retrospectively compiled experi-
ences 21 children (aged 5 to 16 years) received voriconazole
for a median duration of 22 weeks with a time span of one to
50 weeks. Apart from 2 children with recurrent ABPA
receiving the drug as monotherapy in all patients, including
8 children without ABPA but with recurrent Aspergillus
fumigatus isolates, voriconazole was given in combination
with inhaled steroids (in the range of 200 to 2000 mcg of
budesonide). Age adjusted doses of voriconazole were used
but no medication’s blood levels were measured. All
patients had previously been treated with itraconazole. The
authors suggest that they can show that voriconazole may be
a useful adjunct to therapy for ABPA or might be an
alternative treatment strategy when oral corticosteroids are
not suitable.
Whether this speculative conclusion is true and whether
this treatment is of any value cannot be answered by this
retrospective case note review. In fact a report of this kind
should not have been accepted by a peer reviewed journal. It
becomes a retrospective review of a number of observations
and reports dealing with the use of antifungals in ABPA. In
the Cochrane reviews on the use of antifungals in CF, 15
studies published from 1988 to 2003 are listed and none of
these fulfills the criteria for acceptance as a randomized
control trial (RCT). Four are case reports, 11 studies are not
randomized or have no control group.
Due to this dilemma, the Consensus Conference for
treating ABPA in CF patients, which was held in June 2001
in Bethesda, Maryland, summarized their conclusions in a
paper of 39 pages in the Journal for Clinical Infectious
Diseases. The specialists propose plans for managing
various clinical conditions, however, could not define clear
general therapeutic guidelines for the treatment of ABPA in
CF patients. The difficulties already start with the criteria for
a concise and firm diagnosis of ABPA. It is still unclear
whether a rise in total serum IgE and IgG precipitin lines
together with clinical deterioration in the presence or
absence of A. fumigatus in cultured bronchial secretions
or from pharyngeal swabs, respectively, are sufficient to
diagnose ABPA. While in asthmatic patients the use of1569-1993/$ - see front matter D 2005 European Cystic Fibrosis Society. Publish
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fumigatus antigens are highly specific for active disease this
is not the case for CF patients. What is the significance of A.
fumigatus in sputum and how does it relate to the clinical
condition? It is unclear when sensitization begins and when
it is related to the first culture of A. fumigatus. Why do some
patients develop ABPA and why others do not?
Furthermore, it is unclear whether oral or inhaled
corticosteroids have any therapeutic effect. In historic
reports no treatment resulted in bad outcome in some
patients but many recovered without any intervention at all.
There is no true placebo controlled study in the literature
and all recommendations for the treatment of ABPA are
based on limited evidence in the literature.
Still there is no consensus of how, how long, why and
when antifungal drugs in the treatment of ABPA or
Aspergillus colonisation should be used or not. There is
no concentrated action by physicians to jointly conduct
studies and RCT trials are urgently needed. The pressure of
companies to introduce new drugs, the difficult clinical
situation in the chronically ill patients, the lack of human
resources for treating difficult patients and the need to
publish papers by physicians and researchers are all together
impeding the freedom of setting-up good studies. Better
examples can be seen in pediatric oncology. The strict
adherence to treatment was dominantly responsible for the
improvement of the survival i.e. in lymphoma and leukemia
in childhood. In children with cancer there is a one or
nothing situation, in CF treatment urgent therapies are rarely
needed.
Why has the paper by Hillard et al. been published? It
was not published because it is a good scientific study but
because it is an honest report of what is really going on in
the clinical setting of a CF clinic. In fact you can find
published evidence and retrospective reports that support
their treatment by oral and inhaled corticosteroids, alone or
along with antifungals. In some other reports even
methotrexate or monthly infusions of intravenous immuno-
globulins have been said to be of benefit.
This report of Hillard et al. clearly reflects the main-
stream of therapy in a field where no concerted actions are
taken and new fashioned trends for therapy are based on one4 (2005) 213–214ed by Elsevier B.V. All rights reserved.
Editorial214or two observations. The report does not answer whether we
should use the new drug or not and the authors are fair in
saying that it might, however, be worth to try to use
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